Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.81 ▲ +0.00
(0.00%)
MKT CAP: $66.9M • VOL: 8.4K
52W L $5 52W H $8
CSBR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-30 | FY 2024
FILED 2025-04-30 | FY 2023
FILED 2024-04-30 |
|---|---|---|---|
| Revenue (Total Sales) | $59.4M | $56.9M | $50.2M |
| YoY Revenue Growth % | +4.4% | +13.5% | — |
| Gross Profit | $28.5M | $28.6M | — |
| Gross Margin % | 48.0% | 50.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.1M | $4.6M | -$7.4M |
| Operating Margin % | -1.9% | 8.0% | -14.7% |
| Net Income (GAAP) | -$1.2K | $4.7K | -$7.3K |
| EBITDA (Normalized) | -$688.8K | $4.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.5M | $7.4M | -$6.1M |
| Capital Expenditures (CapEx) | $564.0K | $389.0K | — |
| Free Cash Flow (FCF) | -$5.0M | $7.0M | -$6.1M |
| FCF Margin % | -8.5% | 12.3% | -12.2% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $7.1M | $3.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.3M | $5.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CSBR.